This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Continued strategic focus on North America: US market accounts for anywhere between 30 per cent to 60 per cent of annual revenues for Leading Pharmaceuticalcompanies in India. Companies will continue to acquire leadership capabilities with focus on these markets.
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceuticalcompanies.
The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. Their analysis projected that the market will exceed a value of $15.46 billion by 2032.
Amgen drugdevelopment highlights – November 2023 In November 2023, Phase II trial results for immunotherapy tarlatamab demonstrated an ability to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer trial patients.
Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
FDA publishes paper on AI/ML in drugdevelopment In 2022, North America had the largest revenue share in the global pharmaceutical quality management systems market, according to the report. These solutions eliminate the need for on-premise servers and hardware, reducing IT infrastructure costs for pharmaceuticalcompanies.
Recognising the pharmaceutical industry’s substantial contribution to India’s exports, we eagerly anticipate schemes that provide fiscal incentives to encourage such exports. Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030. This may fuel innovation, particularly for diseases prevalent in India.
This is due to these companies looking to meet to the varied needs of pharmaceuticaldevelopers, according to the authors. Increasing the outsourcing of manufacturing activities is helping pharmaceuticalcompanies to focus on their core capabilities. percent between 2022-2030.
Known as biosimilars, these biopharma products are highly similar to innovator products and have no clinically meaningful dissimilarities, especially in terms of efficacy, safety or quality. Indian pharma players could play a key role in positioning biosimilars as superior products to costly biologics.
Patents are often described as the ‘lifeblood’ of pharmaceuticalcompanies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 2020-02-24.
Charles assists clients across a range of FDA-related regulatory matters by providing timely strategic advice on new drug and biologic development and helping them tackle complex regulatory issues.
FDA regulator and founder of Barragan BioConsulting, where she offers Regulatory and Compliance consulting services to pharmaceuticalcompanies globally.
The world’s biggest pharmaceuticalcompany Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. ” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.”
M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Pharmaceutical Technology Excellence Rankings – The Verdict. Solvias is a Swiss-based pharmaceuticalcompany focused on contract research, development and manufacturing. HQ ADDRESS: Römerpark 2.
Sasmitha Sahu, Managing Consultant, GlobalData states, “While India has demonstrated success in generic drug production, the same is not true for novel and biosimilar biopharma products.” ” Embrace technology to transform: Experts and observers also believe that technology will be the true game-changer.
For clinical trials, the Pulse offers researchers and pharmaceuticalcompanies the ability to capture a full suite of vascular biomarkers necessary to characterize the hemodynamic status of clinical trial participants at their homes and transmit the data directly to the study personnel analyzing the impact of intervention being studied.
The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. These highlight the parent company’s focus on innovative and high-value drugdevelopment.
Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.
The company is a clinical-stage biopharmaceutical startup that uses its artificial intelligence (AI)-enabled platform to measure brain biomarkers, including electroencephalogram (EEG) activity and behavioural patterns, wearable data, genetics and other factors, to drive targeted drugdevelopment in mental health.
The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceuticalcompanies. The proposed changes aim to reduce the time between new drug launches in the 27 EU markets and the entry of generic competitors into the market.
4,6 Five patent issues that European biosimilardevelopers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. BMB Reports. 2017;50(3):111–6. Premier Consulting [Internet].
As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drugdevelopment for cost reduction, timely innovation, and generating less waste than the standard process. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.
Moreover, the ceaseless trials of pharmaceuticalcompanies in the research of drugs for several disease conditions have transformed the course of therapeutics.
The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research or NC3Rs has worked with the pharmaceutical industry, researchers and regulators to develop guidance on several related issues in line with its objectives. This approach to more pragmatic regulation is also trending globally.
Pharmaceutical sales in Brazil reached $17bn in 2021, according to GlobalData figures. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceuticalcompanies of international origin within the country. Brazilian public spending on healthcare, drug pricing reforms and remote medicine.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content